TABLE 1.

Virological and immunological characteristics of animals in each study group^b

Infection or treatment status	Monkey code	Duration of infection (days)	Duration of ARV (days)	Time after ARV interruption (days)	Plasma viral load (copies/mL)	CD4 T-cell count/mm3 in blood	Specimen typec
							Blood	MLNs
Uninfected	PB030	NAa	NA	NA	NA	1,084	Yes	No
	PB033	NA	NA	NA	NA	851	Yes	No
	PB036	NA	NA	NA	NA	1,027	Yes	No
	PB046	NA	NA	NA	NA	590	Yes	No
	PB049	NA	NA	NA	NA	457	Yes	No
	PB051	NA	NA	NA	NA	825	Yes	No
	PB061	NA	NA	NA	NA	1,715	Yes	No
	PB057	NA	NA	NA	NA	2,338	Yes	No
	9052732	NA	NA	NA	NA	1,325	Yes	Yes
	9071222	NA	NA	NA	NA	2,492	Yes	Yes
Early untreated	PB006	11	NA	NA	2.80E+07	1,044	Yes	No
	PB041	11	NA	NA	1.90E+06	555	Yes	No
	PB005	14	NA	NA	5.80E+06	473	Yes	No
	PB051	14	NA	NA	4.70E+07	917	Yes	No
	PB015	29	NA	NA	1.10E+06	1,300	Yes	Yes
	PB033	29	NA	NA	6.50E+06	673	Yes	Yes
	9051222	33	NA	NA	1.60E+06	636	Yes	Yes
	PB044	33	NA	NA	7.10E+05	738	Yes	No
	PB023	36	NA	NA	5.70E+06	415	Yes	No
	PB028	36	NA	NA	2.30E+06	553	Yes	No
	PB055	36	NA	NA	3.20E+07	1,261	Yes	Yes
	PB030	46	NA	NA	2.10E+07	61	Yes	Yes
	9082012	60	NA	NA	1.70E+04	805	Yes	Yes
Early ARV treated	R110806	11	7	NA	5.80E+02	1,393	Yes	Yes
	11-1466R	14	10	NA	0.00E+00	1,550	Yes	Yes
	R110804	14	10	NA	0.00E+00	1,912	Yes	No
	R110562	27	23	NA	0.00E+00	1,314	Yes	Yes
	11-1430R	28	24	NA	0.00E+00	3,496	Yes	No
	R110360	35	31	NA	0.00E+00	734	Yes	Yes
	R110482	35	31	NA	0.00E+00	2,945	Yes	No
	13-1660R	36	32	NA	0.00E+00	861	No	Yes
	12-1836R	55	51	NA	0.00E+00	922	Yes	Yes
Early ARV interrupted	R110482	72	56	12	1.10E+05	2,186	Yes	Yes
	12-1888R	72	56	12	7.66E+05	1,450	Yes	Yes
	R110804	75	56	15	3.71E+03	899	Yes	Yes
	12-1134R	75	56	15	3.49E+07	1,010	Yes	Yes
	11-1430R	78	56	18	3.08E+05	1,274	Yes	Yes
Chronic	PB023	167	NA	NA	1.39E+08	254	Yes	Yes
	PB013	188	NA	NA	3.57E+06	764	Yes	Yes
	PB028	194	NA	NA	1.61E+08	370	Yes	No
	PB044	223	NA	NA	5.71E+07	756	Yes	Yes

^aNA, nonapplicable.

^bBlood specimens from three untreated animals were assessed longitudinally in uninfected and early untreated groups (PB030, PB033, PB051), three other untreated animals were assessed longitudinally in both early untreated (acute) and chronic phases (PB023, PB028, PB044), and three early ARV-treated animals were assessed longitudinally in both early ARV-treated and early ARV-interrupted groups (R110482, R110804, 11-1430R).

^cYes represent that a sample was taken, while No represents that no sample was taken.